Translational research in neurology and neuroscience 2010

Multiple sclerosis

Olaf Stuve, Bernd C. Kieseier, Bernhard Hemmer, Hans Peter Hartung, Amer Awad, Elliot Frohman, Benjamin Greenberg, Michael K. Racke, Scott S. Zamvil, J. Theodore Phillips, Ralf Gold, Andrew Chan, Uwe Zettl, Ron Milo, Ellen J Marder, Omar Khan, Todd N. Eagar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

Original languageEnglish (US)
Pages (from-to)1307-1315
Number of pages9
JournalArchives of Neurology
Volume67
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Translational Medical Research
Autoimmune Experimental Encephalomyelitis
Neurology
Neurosciences
Multiple Sclerosis
United States Food and Drug Administration
Animal Models
Biomarkers
Clinical Trials
Drug Therapy
Pharmaceutical Preparations
Translational Research
Neuroscience
Natalizumab
Glatiramer Acetate
Animal Model
Pharmaceuticals
Food and Drug Administration
Clinicians
Pharmacotherapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Translational research in neurology and neuroscience 2010 : Multiple sclerosis. / Stuve, Olaf; Kieseier, Bernd C.; Hemmer, Bernhard; Hartung, Hans Peter; Awad, Amer; Frohman, Elliot; Greenberg, Benjamin; Racke, Michael K.; Zamvil, Scott S.; Phillips, J. Theodore; Gold, Ralf; Chan, Andrew; Zettl, Uwe; Milo, Ron; Marder, Ellen J; Khan, Omar; Eagar, Todd N.

In: Archives of Neurology, Vol. 67, No. 11, 11.2010, p. 1307-1315.

Research output: Contribution to journalArticle

Stuve, O, Kieseier, BC, Hemmer, B, Hartung, HP, Awad, A, Frohman, E, Greenberg, B, Racke, MK, Zamvil, SS, Phillips, JT, Gold, R, Chan, A, Zettl, U, Milo, R, Marder, EJ, Khan, O & Eagar, TN 2010, 'Translational research in neurology and neuroscience 2010: Multiple sclerosis', Archives of Neurology, vol. 67, no. 11, pp. 1307-1315. https://doi.org/10.1001/archneurol.2010.158
Stuve, Olaf ; Kieseier, Bernd C. ; Hemmer, Bernhard ; Hartung, Hans Peter ; Awad, Amer ; Frohman, Elliot ; Greenberg, Benjamin ; Racke, Michael K. ; Zamvil, Scott S. ; Phillips, J. Theodore ; Gold, Ralf ; Chan, Andrew ; Zettl, Uwe ; Milo, Ron ; Marder, Ellen J ; Khan, Omar ; Eagar, Todd N. / Translational research in neurology and neuroscience 2010 : Multiple sclerosis. In: Archives of Neurology. 2010 ; Vol. 67, No. 11. pp. 1307-1315.
@article{c3a1cd52e9f54454b35e8c8776e71ce2,
title = "Translational research in neurology and neuroscience 2010: Multiple sclerosis",
abstract = "Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.",
author = "Olaf Stuve and Kieseier, {Bernd C.} and Bernhard Hemmer and Hartung, {Hans Peter} and Amer Awad and Elliot Frohman and Benjamin Greenberg and Racke, {Michael K.} and Zamvil, {Scott S.} and Phillips, {J. Theodore} and Ralf Gold and Andrew Chan and Uwe Zettl and Ron Milo and Marder, {Ellen J} and Omar Khan and Eagar, {Todd N.}",
year = "2010",
month = "11",
doi = "10.1001/archneurol.2010.158",
language = "English (US)",
volume = "67",
pages = "1307--1315",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Translational research in neurology and neuroscience 2010

T2 - Multiple sclerosis

AU - Stuve, Olaf

AU - Kieseier, Bernd C.

AU - Hemmer, Bernhard

AU - Hartung, Hans Peter

AU - Awad, Amer

AU - Frohman, Elliot

AU - Greenberg, Benjamin

AU - Racke, Michael K.

AU - Zamvil, Scott S.

AU - Phillips, J. Theodore

AU - Gold, Ralf

AU - Chan, Andrew

AU - Zettl, Uwe

AU - Milo, Ron

AU - Marder, Ellen J

AU - Khan, Omar

AU - Eagar, Todd N.

PY - 2010/11

Y1 - 2010/11

N2 - Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

AB - Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

UR - http://www.scopus.com/inward/record.url?scp=77957949997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957949997&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.158

DO - 10.1001/archneurol.2010.158

M3 - Article

VL - 67

SP - 1307

EP - 1315

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -